Background {#Sec1}
==========

Chronic obstructive pulmonary disease (COPD) remains a significant contributor to healthcare resource use due to its considerable morbidity and mortality. According to data at 2012, an estimated 1.2 million people in the UK had diagnosed COPD, and it is now the third leading cause of death globally \[[@CR1], [@CR2]\].

Inhaled bronchodilators, such as long-acting β2 agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), are commonly used for symptom management in patients with COPD \[[@CR3]\]. These can be prescribed as monotherapies, in fixed dose combinations or in combination with inhaled corticosteroids (ICS).

LABA+LAMA combinations have been shown to improve lung function and breathlessness, and reduce exacerbations compared to ICS + LABA treatment \[[@CR4]--[@CR7]\]. Further, studies have shown that overuse of ICS therapies is associated with increased risk of complications such as oral candidiasis, hoarse voice, skin bruising, pneumonia and fractures \[[@CR2], [@CR8]--[@CR13]\]. As a result, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 strategy recommends combination bronchodilator therapy for patients with stable COPD to prevent or reduce symptoms, and that ICS-containing therapies should be reserved for patients categorised as group C or D; i.e. exacerbating patients (≥ 2 or ≥ 1 requiring hospitalisation) \[[@CR2]\].

ICS is indicated for the treatment of patients with moderate-to-severe COPD and a history of exacerbations. Despite this, several studies have found that this does not reflect current clinical practice, and ICS is commonly prescribed in patients with less severe COPD \[[@CR3], [@CR14]--[@CR17]\].

Some clinicians have advocated prescribing of ICS to patients with less severe disease in specific subgroups, e.g. those with asthma--COPD overlap features or elevated peripheral blood eosinophil count, with the goal of preventing exacerbations and thereby reducing healthcare resource use. This may be partially attributed to guidance issued by the National Institute of Health and Care Excellence (NICE) in 2010, which recommended ICS + LABA therapy for patients with forced expiratory volume in 1 s (FEV~1~) \<  50% predicted and remain breathless or have exacerbations despite maintenance LABA therapy \[[@CR18]\]. There is little published evidence on the healthcare resource implications resulting from earlier initiation of ICS. Large randomised controlled trials of ICS use have mainly enrolled patients with severe COPD and frequent exacerbations, and have limited follow-up. Real world data can supplement those from randomised controlled trials by providing more detailed healthcare utilisation and longer-term follow-up.

This study therefore aimed to supplement the existing evidence by investigating the prescribing patterns in the UK for a large cohort of COPD patients in GOLD groups A and B (0 or 1 exacerbation not requiring hospitalisation) \[[@CR17]\], and evaluate the impact of ICS use in in terms of healthcare resource utilisation.

Methods {#Sec2}
=======

Study design, participants, and setting {#Sec3}
---------------------------------------

This was a descriptive, population-based longitudinal study using routinely collected healthcare data provided by the Clinical Practice Research Datalink (CPRD). CPRD contains electronic primary care records from general practice in the UK, and is one of the largest databases of longitudinal medical records from primary care in the world \[[@CR19]\]. The quality of data in CPRD is subject to rigorous checks and regular audits, and has been used to conduct a large number of published pharmacoepidemiologic studies \[[@CR20]--[@CR22]\]. Linkage between CPRD and Hospital Episode Statistics (HES) data is also available, enabling individual anonymised patient records to be followed across care sectors.

For inclusion in the study, patients were required to be of acceptable patient standard (as defined by CPRD), registered with "up-to-standard" practices for the period of observation, and eligible for linkage with HES. The study population included patients aged ≥40 years with a new diagnosis of COPD (based on any record of a diagnostic read code for COPD in addition to spirometry confirmation of the diagnosis \[FEV~1~/forced vital capacity {FVC} ratio \<  0.7\]) during the study period (1 July 2005 to 30 June 2015) and classified as GOLD category A/B (captured according to exacerbation history). Exacerbations were defined using a validated CPRD algorithm (antibiotic and oral corticosteroid prescriptions for 5--14 days calculated using date of prescription and drug pack information, or lower respiratory tract infection read code or acute exacerbation read code) \[[@CR23]\]. The accuracy of COPD diagnosis in CPRD has been validated \[[@CR24]\]. Patients were also required to have a prescription of maintenance bronchodilators within three months of diagnosis, and at least one full year of data prior to the index date (date of the last prescription within three months of diagnosis date). Patients with a diagnostic read code for asthma within one year or those with a record of treatment with a LAMA, LABA, ICS or any combination of these in the year prior to the index date, were excluded. The read codes applied are available in the Additional file [1](#MOESM1){ref-type="media"}.

Outcomes of interest {#Sec4}
--------------------

In order to quantify healthcare resource use in the population under consideration, the following all-cause outcomes were accumulated: number of interactions with a healthcare practitioner (HCP); number of hospital admissions; and number of short-acting bronchodilator prescriptions (i.e. rescue therapy). These endpoints were also assessed according to respiratory-related (as opposed to all-cause) read codes; however, this was considered a supplementary exploratory assessment due to the requirement to considerably restrict read codes to those exclusively associated with COPD (i.e., read codes for breathlessness and chest pain were excluded since these could not be exclusively be attributed to COPD; see Additional file [1](#MOESM1){ref-type="media"}). Treatment costs were not considered.

Analysis {#Sec5}
--------

After identification of records meeting inclusion criteria, patients were stratified according to their prescription at index date and followed until the first of: discontinuation of treatment; last record of treatment plus 28 days (to allow for treatment period); date of initiation of an alternative treatment (i.e. switch from ICS- to non-ICS-containing treatment or vice versa) less one day; patient's transfer out of practice; practice last collection date; end of study period; or death. The ICS group contained patients prescribed ICS as part of maintenance therapy in any combination or alone; the non-ICS group contained patients prescribed any regimen not including ICS.

Patients in the ICS and non-ICS groups were propensity score matched to account for potential biases, as well as to adjust for the difference in individual comorbidities (body mass index \[BMI\] kg/m^2^, modified Medical Research Council \[mMRC\] score, FEV~1~ \[% predicted\], diagnosis of type 2 diabetes, diagnosis of osteoporosis, previous stroke, previous pneumonia, prior exacerbations, Index of Multiple Deprivation \[IMD\]). Propensity scores were created using a published logistic regression model \[[@CR17]\]. Groups were pair matched by propensity score at a ratio of 1:1 using a greedy nearest-neighbour matching algorithm. Pairs were matched on the logit of the propensity score, and calipers of width equal to one standard deviation of the logit of the propensity score were used.

A comparison of baseline characteristics across the two treatment groups was performed using Χ^2^ or T-tests and paired T-tests and McNemar tests for matched comparisons, as appropriate. Prevalence was calculated for binary or categorical characteristics, and mean and standard deviation for continuous characteristics. Missing data were quantified for each variable. For the majority of variables, data were considered to be missing at random (unlikely to bias the estimated results) and classified as unknown.

Outcomes of interest were compared for the ICS and non-ICS groups, with subgroup analyses assessing the impact of potentially relevant confounders; this included group A/B patients with FEV~1~ \<  50% predicted, one prior exacerbation (i.e. removal of patients that had not experienced an exacerbation) and an eosinophil count \> 0.3 × 10^9^/L (selected based on recent literature that suggested a benefit of ICS in patients with an eosinophil count above this level) \[[@CR17], [@CR25], [@CR26]\]. Rate ratios were estimated using zero-inflated negative binomial regression of the number of events, in order to take into account individuals more prone to repeated events and provide more conservative confidence intervals and *p* values. We compared a univariate analysis with the fully adjusted model.

Results {#Sec6}
=======

A total of 4009 patients with newly diagnosed GOLD A/B COPD and a prescription for maintenance bronchodilation treatment within three months of diagnosis were identified (see Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Patient selection flow chart. COPD, chronic obstructive pulmonary disease; CPRD, Clinical Practice Research Datalink; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HES, Hospital Episode Statistics; ICS, inhaled corticosteroid

The treatments prescribed to patients within three months of COPD diagnosis are displayed in Fig. [2](#Fig2){ref-type="fig"}; 44% of the cohort was prescribed an ICS-containing regimen.Fig. 2Treatments prescribed within three months of COPD diagnosis. COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting β2 agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting β~2~ agonist; SAMA, short-acting muscarinic antagonist

There was no statistically significant difference between most groups prior to propensity score matching; following matching, any differences between groups were controlled for. After matching, 531 patients were excluded, leaving a total matched-cohort size of 3478.

On average, patients had 31 months of follow-up (standard deviation \[SD\] 24 months). Total patient years of follow up were 4348 in the ICS group versus 4686 in the non-ICS group. As the mean difference in follow-up time was minimal, no adjustment was made in the subsequent analysis.

Baseline characteristics of the study population pre- and post-matching are shown in Table [1](#Tab1){ref-type="table"}. In the total matched cohort, there were more male than female patients (60.5% versus 39.5%) and the mean age was 67.8 years (SD: 10 years). On average, patients were diagnosed between 2009 and 2013 (mean: 2011; SD: 2 years). Just under half (47.9%) had a BMI greater than 25 kg/m^2^, and 42.4% were current smokers. Similar proportions of patients had comorbid type 2 diabetes (15.4%), asthma diagnosed more than one year prior to COPD diagnosis (16.6%) and an eosinophil count \> 0.3 × 10^9^/L (18.2%).Table 1Patient baseline demographics and characteristics pre- and post-matchingParameterPre-matchingPost matchingICS (*N* = 1745)Non-ICS (*N* = 2264)*P* valueICS (*N* = 1739)Non-ICS (*N* = 1739)*P* valueFemale, *n* (%)679 (38.9)906 (40.0)0.494676 (38.9)697 (40.1)0.480Mean age, years (SD)67.6 (10.3)68.0 (10.3)0.23767.6 (10.3)67.9 (10.2)0.480Mean BMI, kg/m^2^ (SD)27 (5.8)27 (5.8)0.418927 (5.8)27 (6.0)0.3166Mean FEV~1~ predicted, % (SD)57 (19.4)61 (18.5)\<  0.00157 (19.4)61 (18.5)\<  0.001Age category, n (%) 40--44 years29 (1.7)26 (1.1)0.32127 (1.6)21 (1.2)0.143 45--54 years171 (9.8)201 (8.9)171 (9.8)153 (8.8) 55--64 years455 (26.1)618 (27.3)454 (26.1)479 (27.5) 65--74 years628 (36.0)777 (34.3)626 (36.0)603 (34.7) 75--80 years275 (15.8)369 (16.3)274 (15.8)270 (15.5) \>  80 years187 (10.7)273 (12.1)187 (10.8)213 (12.2)BMI category, n (%) Underweight (\<  18.5)79 (4.5)78 (3.4)0.07679 (4.5)55 (3.2)0.235 Normal (18.5--24.9)512 (29.3)662 (29.2)512 (29.4)509 (29.3) Overweight (25--29.9)436 (25.0)629 (27.8)434 (25.0)484 (27.8) Obese (30--39.9)361 (20.7)418 (18.5)358 (20.6)325 (18.7) Severely obese (≥ 40)26 (1.5)47 (2.1)26 (1.5)39 (2.2) Missing331 (19.0)430 (19.0)330 (19.0)327 (18.8)Smoking status, *n* (%) Current726 (41.6)994 (43.9)0.097725 (41.7)750 (43.1)0.513 Non-smoker/never smoked90 (5.2)85 (3.8)88 (5.1)67 (3.9) Ex-smoker773 (44.3)972 (42.9)770 (44.3)761 (43.8) Missing156 (8.9)213 (9.4)156 (9.0)161 (9.3)IMD quintile, *n* (%) I292 (16.7)322 (14.2)0.175291 (16.7)249 (14.3)0.254 II326 (18.7)411 (18.2)325 (18.7)313 (18.0) III336 (19.3)438 (19.3)334 (19.2)352 (20.2) IV390 (22.3)526 (23.2)388 (22.3)387 (22.3) V399 (22.9)565 (23.2)399 (22.9)436 (25.1)2017 GOLD classification, *n* (%) GOLD A1044 (59.8)1479 (65.3)\<  0.0011044 (60.0)1068 (61.4)0.356 GOLD B701 (40.2)785 (34.7)695 (40.0)671 (38.6)Comorbidities, *n* (%) Eosinophilia (\>  0.4 × 10^9^/L)119 (6.8)153 (6.8)0.933119 (6.8)127 (7.3)0.942 Eosinophilia (\>  0.3 × 10^9^/L)326 (18.7)399 (17.6)0.683326 (18.7)307 (17.7)0.822 Eosinophilia (read code)\<  5 (−)\<  5 (−)0.214\< 5 (−)\< 5 (−)0.942 Asthma diagnosed \> 1 year prior310 (17.8)304 (13.4)\<  0.001304 (17.5)273 (15.7)0.093 Type II diabetes271 (15.5)339 (15.0)0.627270 (15.5)267 (15.4)0.888 Osteoporosis/osteopenia227 (13.0)286 (12.6)0.724227 (13.1)225 (12.9)0.921 Stroke118 (6.8)144 (6.4)0.610117 (6.7)115 (6.6)0.893 Myocardial infarction166 (9.5)238 (10.5)0.297166 (9.5)166 (9.5)1.000 Pneumonia357 (20.5)443 (19.6)0.484356 (20.5)356 (20.5)1.000 Prior exacerbations711 (40.7)895 (39.5)0.437709 (40.8)705 (40.5)0.890*BMI* body--mass index, *FEV*~*1*~ forced expiratory volume in 1 s, *GOLD* Global Initiative for Chronic Obstructive Lung Disease, *ICS* inhaled corticosteroid, *IMD* Index of Multiple Deprivation - where I is most deprived, *SD* standard deviation

Table [2](#Tab2){ref-type="table"} shows the total events in the ICS and non-ICS groups. Fewer short-acting therapy prescriptions were administered in the non-ICS group (*p* \<  0.05). All outcomes, with the exception of respiratory-specific hospital interactions (with a difference of 64 events), were numerically higher for the ICS-containing group. Although not statistically significant, 'all HCP interactions' approached significance, likely driven by the difference in GP visits between the groups.Table 2Healthcare resource use during study follow-upOutcomeTotalICS versus non-ICSAdjustedUnadjustedICSNon-ICSRelative rate (95% CI)*P* value\*Relative rate (95% CI)*P* value\*Short-acting therapy prescriptions24,06321,1631.05 (0.97--1.14)0.2121.09 (1.01--1.18)0.026All-cause interactions All HCP72,80269,1361.07 (1.00--1.14)0.0611.05 (0.98--1.13)0.156 GP55,92752,9471.07 (1.00--1.14)0.0631.06 (0.98--1.13)0.129 Outpatient13,49712,9891.01 (0.94--1.08)0.8021.04 (0.93--1.16)0.485 Hospital337832001.05 (0.93--1.19)0.4341.06 (0.94--1.19)0.377Respiratory-related interactions All HCP^a^20,55519,5431.04 (0.98--1.12)0.2091.05 (0.98--1.13)0.154 Routine GP16,39115,4091.05 (0.99--1.13)0.1271.06 (0.99--1.14)0.078 Unplanned GP216620851.04 (0.92--1.18)0.5061.04 (0.92--1.17)0.530 Outpatient2472341.04 (0.78--1.39)0.8091.06 (0.80--1.40)0.705 Hospital175118150.95 (0.83--1.09)0.4650.96 (0.84--1.10)0.603\*Significant at α = 0.05; ^a^GP + outpatient + hospital*CI* confidence interval, *GP* general practitioner, *HCP* healthcare practitioner, *ICS* inhaled corticosteroid

The direction of relative rates favoured non-ICS containing therapy in all outcomes, with the exception of respiratory-specific hospital interactions (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Forest plot of rate ratios for outcomes assessed. HCP, healthcare practitioner; GP, General Practitioner; RR, respiratory-related; RRR, routine respiratory-related; SABA, short-acting β~2~ agonist; SAMA, short-acting muscarinic agonist; URR, unplanned respiratory-related

Subgroup analyses showed similar trends, with adjusted outcome relative rates generally favouring the non-ICS group. Figure [4](#Fig4){ref-type="fig"} demonstrates this for three key patient subgroups.Fig. 4Rate ratios for subgroup analyses. **a** Patients with one previous exacerbation. **b** Patients with an eosinophil level \>  0.3 × 109/L. **c** Patients with FEV1 \<  50% predicted. HCP, healthcare practitioner; GP, General Practitioner; RR, respiratory-related; RRR, routine respiratory-related; SABA, short-acting β2 agonist; SAMA, short-acting muscarinic agonist; URR, unplanned respiratory-related

Discussion {#Sec7}
==========

CPRD, when linked to HES, provides an important repository of data regarding the diagnosis, treatment and ongoing care of UK patients from the primary to the secondary care setting. According to analysis of this data, almost half of GOLD A/B COPD patients were prescribed an ICS-containing regimen between 2005 and 2015. Despite the widespread use of ICS, no significant differences in rate of healthcare resource use were identified in this study.

In pertinent subgroups of GOLD A/B patients in which escalation to ICS is sometimes advocated in clinical practice, i.e. those who have experienced an exacerbation, have poorer lung function or have elevated eosinophils, the benefit is uncertain. Recent trials of ICS have enrolled patients with a history of only one exacerbation in the prior year (which results in a classification of GOLD A/B). Recent evidence, including from the FLAME study, has demonstrated that bronchodilators can be equally or more effective in preventing exacerbations compared to ICS/LABA \[[@CR5]\]. Blood eosinophil counts have been advocated as a biomarker to predict ICS response, and influential authors have advocated ICS use in patients with eosinophil counts \> 2% or \>  0.3 × 10^9^/L. There are caveats regarding this analysis, specifically that most evidence for prediction of ICS response from eosinophil counts is from post-hoc analyses of prior studies, and most studies enrolled severe patients with a history of frequent exacerbations. For patients with poorer lung function, there is a conflict between the 2010 NICE guidelines \[[@CR18]\], which advocate ICS/LABA use for patients with FEV~1~ \<  50% predicted, and the GOLD 2017 strategy \[[@CR2]\], which promotes ICS use only for patients with two or more exacerbations (or one hospital admission) in the previous year.

It should be noted that this study was not designed to observe the clinical impact of ICS and its potential benefit to some patients; however, the finding that these key patient subgroups do not seem to experience any benefit from initial ICS therapy in terms of HCP interactions is important in view of the current debate on the role of ICS. The rationale for the addition of ICS in these patients, which is contrary to GOLD guidelines \[[@CR2]\], should be considered in the context of these findings.

Limitations in read coding meant that conclusions were more difficult to draw for respiratory-related outcomes, and results of this analysis should be interpreted with caution; however, results appear supportive of the primary findings.

On visual inspection, baseline demographics and clinical characteristics of the treatment groups are considered representative of those seen in clinical practice. In terms of patient numbers, a considerable proportion of the starting cohort were excluded at the point of requiring a read code for confirmed spirometry; a record of spirometry confirmed COPD is considered essential to ensure the analysis cohort represented true COPD patients (and not those that actually had asthma or other respiratory condition) \[[@CR24]\]. In spite of this, patient numbers were large enough to statistically power the analysis.

Prior to analysis, the matching process attempted to correct for potential biases; however, common to all CPRD analyses, certain biases (e.g. practitioner read code fluency) cannot be ruled out. It is, however, considered that the results of this study are largely generalisable to the UK.

Conclusions {#Sec8}
===========

Despite marketing authorisation, clinical rationale and guideline support for reserving ICS use in more severe patients, ICS is commonly prescribed in patients without exacerbating COPD \[[@CR2], [@CR3], [@CR8]--[@CR13], [@CR15]--[@CR17]\]. This study demonstrates that there is no reduction in healthcare resource use, rather results tended toward an increase, when ICS is prescribed on top of maintenance bronchodilation. This held for important patient subgroups, e.g. those with FEV~1~ \<  50% predicted, a history of exacerbations and an eosinophil count \> 0.3 × 10^9^/L. Results suggest that, within the UK healthcare system, there may be opportunity to improve patient care and potentially reduce resource use for patients receiving maintenance treatment for GOLD A/B COPD.
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BMI

:   Body--mass index

CI

:   Confidence interval

COPD

:   Chronic obstructive pulmonary disease

CPRD

:   Clinical Practice Research Datalink

FEV~1~

:   Forced expiratory volume in 1 s

FVC

:   Forced vital capacity

GOLD

:   Global Initiative for Chronic Obstructive Lung Disease

GP

:   General Practitioner

HCP

:   Healthcare practitioner

HES

:   Hospital Episode Statistics

ICS

:   Inhaled corticosteroid

IMD

:   Index of multiple deprivation

LABA

:   Long-acting β2 agonist

LAMA

:   Long-acting muscarinic antagonist

mMRC

:   Modified Medical Research Council

NICE

:   National Institute of Health and Care Excellence

RR

:   Respiratory-related

RRR

:   Routine respiratory-related

SABA

:   Short-acting β~2~ agonist

SAMA

:   Short-acting muscarinic antagonist

SD

:   Standard deviation

URR

:   Unplanned respiratory-related
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